These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 28636480

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ, Keyloun KR, Higa S, Park J, Bonafede M, Gillard P, Jain R.
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH.
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [Abstract] [Full Text] [Related]

  • 11. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH.
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [Abstract] [Full Text] [Related]

  • 12. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
    Lyons KE, Pahwa R, Hermanowicz N, Davis T, Pagan F, Isaacson S.
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.